EYEGATE PHARMACEUTICALS INC | Business Contracts

Registration Rights Agreement, dated as of February 3, 2023, by and between Kiora Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 3, 2023)

Form of Inducement Letter (Filed With SEC on November 21, 2022)

Consulting Agreement, dated as of March 9, 2022, between Danforth Advisors, LLC and the Company (Filed With SEC on April 26, 2022)

Patent License Agreement, dated as of July 2, 2013, by and between Panoptes Pharma Ges.m.b.H. and 4SC Discovery GmbH (Filed With SEC on March 25, 2021)

First Amendment to Managing Director Service Agreement by and among Panoptes Pharma Ges.m.b.H, EyeGate Pharmaceuticals, Inc. and Dr. Franz Obermayr, dated as of January 29, 2021 (Filed With SEC on February 1, 2021)

Purchase Agreement, dated as of February 3, 2023, by and between Kiora Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 3, 2023)

Registration Rights Agreement, dated as of February 2, 2023, by and between Kiora Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 3, 2023)

Securities Purchase Agreement, dated as of February 2, 2023, by and between Kiora Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 3, 2023)

Form of Warrant (Filed With SEC on February 3, 2023)

Form of Inducement Warrant (Filed With SEC on November 21, 2022)

Offer Letter by and between Kiora Pharmaceuticals, Inc. and Melissa Tosca, dated as of August 18, 2022 (Filed With SEC on September 16, 2022)

Warrant Agency Agreement dated July 22, 2022, by and between Kiora Pharmaceuticals, Inc. and VStock Transfer, LLC (Filed With SEC on July 26, 2022)

Underwriting Agreement dated as of July 22, 2022, by and between Kiora Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on July 26, 2022)

Form of Class A Warrant (Filed With SEC on July 21, 2022)

Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on July 21, 2022)

Form of Class B Warrant (Filed With SEC on July 21, 2022)

Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC (Filed With SEC on July 21, 2022)

Form of Common Stock Purchase Warrant (Filed With SEC on July 19, 2022)

Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on July 19, 2022)

Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC (Filed With SEC on July 13, 2022)

Form of Common Stock Purchase Warrant (Filed With SEC on July 13, 2022)

Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on July 13, 2022)

Separation Agreement by and between Kiora Pharmaceuticals, Inc. and Stephen From, dated January 31, 2022 (Filed With SEC on February 1, 2022)

Employment Agreement by and between EyeGate Pharmaceuticals, Inc., Bayon Therapeutics Pty Ltd and Eric J. Daniels, dated as of October 21, 2021 (Filed With SEC on October 26, 2021)

Stock Purchase Agreement, dated as of October 21, 2021, by and among EyeGate Pharmaceuticals, Inc. and the Sellers listed therein (Filed With SEC on October 26, 2021)

EyeGate Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended (Filed With SEC on August 12, 2021)

Engagement Letter between EyeGate Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, dated as of August 5, 2021 (Filed With SEC on August 10, 2021)

Form of Securities Purchase Agreement (Filed With SEC on August 10, 2021)

Form of Placement Agent Warrant (Filed With SEC on August 10, 2021)

Form of Warrant (Filed With SEC on August 10, 2021)

Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Brian M. Strem, dated as of July 22, 2021 (Filed With SEC on July 26, 2021)

Patent and Know How Assignment Agreement, dated as of July 2, 2013, by and between Panoptes Pharma Ges.m.b.H and 4SC Discovery GmbH (Filed With SEC on March 25, 2021)

Fourth Amended and Restated Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Stephen From, dated as of January 29, 2021 (Filed With SEC on February 1, 2021)

Managing Director Service Agreement by and between Panoptes Pharma Ges.m.b.H and Dr. Franz Obermayr, dated as of December 18, 2020 (Filed With SEC on February 1, 2021)

Form of Warrant (Filed With SEC on January 6, 2021)

Registration Rights Agreement between the Company and Armistice Capital Master Fund, Ltd. dated as of January 5, 2021 (Filed With SEC on January 6, 2021)

Securities Purchase Agreement between the Company and Armistice Capital Master Fund, Ltd. dated as of January 5, 2021 (Filed With SEC on January 6, 2021)

Share Purchase Agreement, dated as of December 18, 2020, by and among EyeGate Pharmaceuticals, Inc. and the Sellers listed therein (Filed With SEC on December 21, 2020)

Registration Rights Agreement, dated as of December 18, 2020, by and among EyeGate Pharmaceuticals, Inc. and the Sellers listed therein (Filed With SEC on December 21, 2020)

Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Sarah Romano, dated as of March 23, 2020 (Filed With SEC on March 24, 2020)

Amendment No. 2 to Sub-License Agreement, dated as of February 17, 2016, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)

Amendment No. 1 to Sub-License Agreement, dated as of September 18, 2015, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)

Exclusive Sub-License Agreement, dated as of September 12, 2013, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)

Description of Securities (Filed With SEC on March 4, 2020)

Engagement Letter between EyeGate Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, dated as of December 30, 2019 (Filed With SEC on December 31, 2019)

Form of Securities Purchase Agreement (Filed With SEC on December 31, 2019)

Form of Placement Agent Warrant (Filed With SEC on December 31, 2019)

EyeGate Pharmaceuticals, Inc. Amended and Restated Change in Control Severance Plan (Filed With SEC on December 3, 2019)

Amendment to Third Amended and Restated Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Stephen From, dated as of November 26, 2019 (Filed With SEC on December 3, 2019)

Securities Purchase Agreement between the Company and Armistice Capital Master Fund, Ltd. dated as of September 29, 2019 (Filed With SEC on September 30, 2019)

Registration Rights Agreement between the Company and Armistice Capital Master Fund, Ltd. dated as of September 29, 2019 (Filed With SEC on September 30, 2019)

Form of Warrant (Filed With SEC on September 30, 2019)

EYEGATE PHARMACEUTICALS INC (52)